Prosecution Insights
Last updated: April 19, 2026

Examiner: PYLA, EVELYN Y

Tech Center 1600 • Art Units: 1600 1633 1651

This examiner grants 55% of resolved cases

Performance Statistics

55.0%
Allow Rate
-5.0% vs TC avg
580
Total Applications
+47.8%
Interview Lift
1389
Avg Prosecution Days
Based on 538 resolved cases, 2023–2026

Rejection Statute Breakdown

5.5%
§101 Eligibility
16.8%
§102 Novelty
40.2%
§103 Obviousness
27.0%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
17911391 COMPOSITIONS AND METHODS FOR MODIFYING A TARGET NUCLEIC ACID Non-Final OA THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
17795915 COMPOSITIONS FOR TRANSLATION AND METHODS OF USE THEREOF Non-Final OA Flagship Pioneering Innovations VI, LLC
18036111 MODULATING BHLHE40 IN THE DIFFERENTIATION OF TYPE 1 REGULATORY T CELLS AND CONTROLLING T CELL EXHAUSTION Non-Final OA The Board of Trustees of the Leland Stanford Junior University
17762396 CELL CULTURING MATERIALS Final Rejection KONINKLIJKE PHILIPS N.V.
17524038 COMPOSITIONS AND METHODS FOR GRAFTS MODIFIED WITH A NON-THROMBOGENIC AND PRO-MIGRATORY CELL-DERIVED EXTRACELLULAR MATRIX Non-Final OA YALE UNIVERSITY
18056367 LIPIDS FOR DELIVERY OF NUCLEIC ACID SEGMENTS Non-Final OA AstraZeneca AB
17609425 AAV MUTANT THAT EFFICIENTLY INFECTS SUPPORTING CELLS Final Rejection CENTER FOR EXCELLENCE IN BRAIN SCIENCE AND INTELLIGENCE TECHNOLOGY, CHINESE ACADEMY OF SCIENCES
17292303 ANCHORAGE-INDEPENDENT CELLS AND USE THEREOF Non-Final OA Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
18304694 METHODS OF CONTROLLING RED BLOOD CELL PRODUCTION Non-Final OA Wisconsin Alumni Research Foundation
18806560 Viral vector packaging cells with tunable virus genes to optimize vector production and quality Non-Final OA CHO Plus, Inc.
18076795 METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE BASED ON HOST-MYCOBIOTA INTERACTIONS Non-Final OA Cornell University
17624744 METHOD FOR PRODUCING CULTURE MEDIUM COMPOSITION FOR SUSPENSION CULTURING ADHERENT CELLS Non-Final OA NISSAN CHEMICAL CORPORATION
17927038 Recombinant P5 Promoter for Use in Reducing DNA Contamination of AAV Preparations Non-Final OA ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC.
18404389 METHODS AND COMPOSITIONS RELATING TO CHONDRISOMES FROM BLOOD PRODUCTS Non-Final OA The Children's Medical Center Corporation
17651056 METHODS AND COMPOSITIONS OF CHONDRISOMES Non-Final OA The Children's Medical Center Corporation
18609070 Use of Short Chain Fatty Acids in Cancer Prevention Non-Final OA Temple University-Of The Commonwealth System of Higher Education
18310100 COMPOSITIONS AND METHODS FOR PREPARATION OF RED BLOOD CELLS Non-Final OA Cerus Corporation
17725324 CRISPR ABASIC RESTRICTED NUCLEOTIDES AND CRISPR ACCURACY VIA ANALOGS Final Rejection Caribou Biosciences, Inc.
17310235 OLIGONUCLEOTIDES AND METHODS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION Final Rejection The Schepens Eye Research Institute, Inc.
17811685 LONG POLY(A) PLASMIDS AND METHODS FOR INTRODUCTION OF LONG POLY(A) SEQUENCES INTO THE PLASMID Non-Final OA Seattle Children's Hospital (dba Seattle Children's Research Institute)
18039027 MEDIUM COMPOSITION FOR DERMAL PAPILLA CELL GROWTH, CONTAINING ROTENONE AND ALBUMIN AS ACTIVE INGREDIENTS Final Rejection XCELL THERAPEUTICS INC.
18024324 DETOXIFIED SECRETOME EXTRACT MADE FROM CULTURE SUPERNATANT OF MESENCHYMAL STEM CELLS OR PROGENITOR CELLS DERIVED FROM THE MESENCHYMAL STEM CELLS, AND METHOD FOR PRODUCING SAME Non-Final OA TELEBIO K.K.
18115728 SCAFFOLD, METHOD FOR PRODUCING SCAFFOLD, CELL CULTURE CONSTRUCT, METHOD FOR CULTURING CELL Final Rejection LEAVE A NEST CO, LTD.
18021864 BURN RESTORATION MATERIAL Non-Final OA SAKURA SEIKI CO., LTD.
15898558 COATED BIOLOGICAL COMPOSITION Non-Final OA Vivex Biologics Group, Inc.
17811418 Bone Marrow Derived CD271 Precursor Cells for Cardiac Repair Final Rejection JMHMD HOLDINGS LLC
17640681 METHOD FOR OBTAINING HEALTHY INTESTINAL ORGANOIDS Non-Final OA PRECISION CANCER TECHNOLOGIES INC.
17453143 FIBROBLASTS FOR TREATMENT OF DEGENERATIVE DISC DISEASE Final Rejection SpinalCyte, LLC
17194855 METHOD OF TREATING THE EFFECTS OF STROKE Final Rejection Central Adelaide Local Health Network Inc
16305910 METHOD FOR PRODUCING A PLATELET-LYSATE-CONTAINING GEL Non-Final OA PL BIOSCIENCE GMBH

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month